AcutaaS Chemicals has officially inaugurated Phase 1 of its new "State of the Art" manufacturing block dedicated to electrolyte additives and battery chemicals production at its Jhagadia facility on January 19, 2026. The company informed stock exchanges about this significant milestone under Regulation 30 of SEBI (LODR) Regulations, 2015. The new facility is expected to add 30% revenue to the company's annual production.

Facility Inauguration and Revenue Impact

The newly inaugurated Phase 1 manufacturing block is located at the company's existing Unit-III Jhagadia facility. This development follows the company's earlier intimation to exchanges dated December 11, 2024, regarding the upcoming facility expansion. The dedicated facility for battery chemicals production is projected to contribute significantly to the company's revenue growth.

Strategic Manufacturing Enhancement

This Phase 1 inauguration represents a significant step in AcutaaS Chemicals' expansion strategy in the battery chemicals segment. The dedicated manufacturing block for electrolyte additives and battery chemicals positions the company to capitalize on the growing demand in the battery technology sector. The facility is strategically located at the existing Jhagadia complex, leveraging the company's established infrastructure and operational expertise.

Regulatory Compliance and Disclosure

AcutaaS Chemicals has fulfilled its regulatory obligations by informing both stock exchanges about the facility inauguration. The intimation was made pursuant to Regulation 30 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has made the inauguration details available on its official website at www.acutaas.com , ensuring transparency and accessibility of information for all stakeholders.

Production Capacity Enhancement

The new manufacturing block dedicated to battery chemicals production represents a substantial enhancement to the company's production capabilities. With the potential to add 30% revenue to annual production, this facility inauguration marks a strategic milestone in AcutaaS Chemicals' growth trajectory in the specialized chemicals sector. Company Secretary & Compliance Officer CS Ekta Kumari Srivastava signed the official communication to the stock exchanges.

Acutaas Chemicals Limited , a leading player in the specialty chemicals sector, has announced significant developments in its employee stock option scheme and leadership structure. These strategic moves demonstrate the company's commitment to strengthening its management team and aligning employee benefits with corporate growth objectives.

Major ESOS Grant Under Category II

The Nomination and Remuneration Committee of Acutaas Chemicals has granted 3,25,009 employee stock options under the existing ESOS 2023 scheme. This substantial grant was approved at the committee meeting held on December 22, 2025, and falls within the shareholder-approved limit of 6,68,740 options available under Category II Grant of ESOS 2023.

Vesting Structure and Terms

The granted options feature a hybrid vesting mechanism combining time-based and performance-based components. The vesting schedule is structured to incentivize both tenure and performance:

The performance-based component will be subject to annual review and approval by the NRC, based on key responsibility areas and performance metrics of option grantees. Vested options may be exercised within a maximum period of 2 years from the relevant vesting date.

Leadership Enhancement

The company has designated Mr. Abhishek Haribhai Patel as a Senior Management Person, effective July 30, 2025. Mr. Patel, who has been serving as the Vice President - Strategy since January 8, 2024, brings extensive experience to this elevated role. His association with Acutaas Chemicals includes his previous tenure as Chief Financial Officer from 2018 to 2022, during which he played a pivotal role in the company's successful Initial Public Offering in 2021.

ESOS 2023 Post-Split Adjustments

Following the 1:2 stock split with a record date of April 25, 2025, Acutaas Chemicals made necessary adjustments to its ESOS 2023. The exercise price range was adjusted from Rs. 10.00-610.00 to Rs. 5.00-305.00 per share, while the total number of ungranted options under Category II increased from 3,34,370 to 6,68,740 options. These adjustments maintain the unchanged overall value of employee benefits without requiring additional shareholder approval.

Strong Financial Performance

The company reported robust financial results for the first quarter of FY2026, demonstrating strong operational performance:

Mr. Naresh Patel, Executive Chairman & Managing Director, attributed the strong performance to robust growth in the Pharmaceutical Intermediates business and highlighted the company's recent PMDA GMP certification achievement for both pharma facilities.